Audit: QRS - DIM for Health & Longevity

Audit conducted on 09/09/2026 04:19 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol cells trace to ER lines 338/342/344, time cells to ER line 371, benefit/risk tiers to the ER Expected Benefits and Potential Risks & Side Effects headings, gates to ER lines 306–324, monitoring rows to the ER biomarker table (lines 391–399), qualitative items to ER lines 403–407.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	action_3_sub keeps “No trial compared timing” (ER line 342); the at-a-glance keeps “has never been shown to make anyone healthier” (ER line 422).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Tamoxifen stays a hard contraindication, matching the ER avoid-list (line 319); “Pregnancy or breastfeeding” is kept in the stop gate, not downgraded.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Stop items come only from the ER “Populations who should avoid DIM” list; caution items only from the ER Key Interactions & Contraindications bullets. No content drawn from Benefit-Modifying Factors or Risk-Modifying Factors.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names, or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	The only study references (“the prostate dose-escalation study”, “the cervical dysplasia trial”, “the tamoxifen trial”) are the ER’s own wording for the same facts (ER lines 344, 371).

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Flat, measured, non-promotional register carried over from the ER, including the ER’s own framing that the metabolite shift is the only reliable effect.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and dose ranges alongside plain-language framing; no hedging that would leave the reader without a decision basis.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements are descriptive (“Twice-daily dosing produced stable systemic exposure”), not instructional.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a reader; the footer disclaimer is the template’s.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	monitoring_cadence uses passive reporting (“rechecked at 4–6 weeks”, “repeated at 3 months”) rather than instruction.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to those the ER itself uses and defines (SHBG, TSH, ALT, PSA), each expanded on first use in the monitoring table.
2.8	Information is presented in a concise and very compact manner	🟢	Tier lines are semicolon-separated bare labels; gate items carry no rationale.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text search for second-person forms; none present.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes willingness to run baseline labs, split doses, and screen a medication list.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Nine-biomarker monitoring panel with a staged recheck cadence assumes exactly this audience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification to a “just take one a day” register; interaction and threshold detail is retained.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance states plainly that the reliable effect is a laboratory shift with no demonstrated health benefit — the decision-relevant signal for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register throughout (“gastrointestinal upset”, “asymptomatic hyponatremia”, “thrombophilia”); the plainer at-a-glance wording is the ER’s own conclusion phrasing and is required by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings verified byte-identical to the template: lines 443, 489, 538, 570, 589, 618, 645, 649–651, 794, and the four tier labels in both the benefits and risks cards.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variable names are present; the indexed placeholders marker_#_* and qualitative_item_# are expanded to marker_1..9_* and qualitative_item_1..5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A structural diff against the template shows changes only inside variable spans, plus the display: none on benefits_high that item 12.5 requires. CSS, markup, comments, and the footer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the ER Expected Benefits High tier carries a prose statement rather than an empty-state phrase, and item 12.5 governs its handling.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label / action_2_label / action_3_label reproduce the ER bold labels “Standard supplement dose”, “Single versus split dose”, “Best time of day” verbatim; caution items reproduce the ER interaction bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit and risk items reuse the ER’s own sub-section headings; monitoring marker names and “Why” strings are verbatim from the ER biomarker table.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-text search returns no emoji characters; the ER’s “⚠️ Conflicted” markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to its minimum permitted form — tier lines are bare labels, gate items carry no rationale, protocol subs are one to two sentences — while still satisfying the mandatory completeness items 8.5, 9.5, 14.2, and 15.2.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14: the comment opens immediately after <!doctype html> on line 1 and closes before <html lang="en">.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	It sits entirely inside an HTML comment and no metadata value is repeated in the header, body, or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: dim_2026-0909-0002_Opus_ER.md, matching the ER’s own filename frontmatter value.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0909-0413, correctly formatted.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number, with no context-window or tier qualifier appended.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: dim_2026-0909-0002_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; only the colon-bearing duration value is quoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 20: DIM for Health & Longevity - Quick Reference Sheet, matching the ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 415: DIM for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 419: 09/09/2026, the correct reformatting of 2026-0909-0413.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 423: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template’s own subline; the ER’s alternate_names line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	All three sentences condense the ER Conclusion (lines 422–424): what it is, the one reliable effect, and the tolerability/dose-ceiling picture.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Sentence 1 → ER line 422 opening; sentence 2 → ER line 422 middle; sentence 3 → ER line 424.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “cabbage-family vegetables”, “less active form”, “stomach upset”, and “low blood sodium” are used in place of glucosinolate, 2-hydroxylation, gastrointestinal, and hyponatremia.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes, or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items map to the “Populations who should avoid DIM” list at ER lines 319–324.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER avoid-list entries are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 573–584: six discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationale “since no reproductive safety data exist” and the appositive “(an inherited clotting tendency)” are stripped; no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within the past 6 months”, “(factor V Leiden)”, “below 135 mmol/L”, the thiazide names, and the SSRI names are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s avoid list uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map to the interaction bullets at ER lines 307–315.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Nine of the ER’s ten interaction bullets appear; “Tamoxifen” is correctly excluded because it is carried in the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 592–608: nine discrete <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every item is reduced to the ER’s bold label plus its drug list; the “Monitor”/”Caution” verdicts and mechanistic sentences that follow each ER bullet are dropped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Drug lists are retained for every item that has one, including the two supplement classes whose examples the ER carries in the bullet body; the CYP1A2 list is trimmed to four representatives rather than dropped.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER interaction bullets use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol bullets at lines 338, 342, and 344.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, dosing frequency, and timing — the three decisions a reader must make before taking the compound — are selected ahead of the ER’s genotype, sex, age, and competing-approach bullets.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section carries twelve actionable bullets, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; none is a placeholder or an empty-state phrase.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s “Time to effect” bullet (line 371) names exactly three horizons — metabolite shift, body composition, and clinical endpoints — and all three are carried.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Body composition (the ER’s only Medium-tier benefit) is first, the metabolite shift (Low tier) second, and clinical endpoints (no established benefit) last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry ER-derived content, with the value cells (“30 days”, “Within 4 weeks”, “6–12 months”) taken directly from ER line 371.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every listed item is an ER Expected Benefits sub-heading, in ER order within each tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 540, 544, 550, and 558.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a semicolon-separated list of bare ER headings; no “Magnitude” figures, p-values, sample sizes, or trial names are carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four benefit tiers.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No benefit reaches High” (line 146), and benefits_high carries style="display: none" with an HTML comment recording the ER basis; no empty-state phrasing is rendered.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Every listed item is an ER Potential Risks & Side Effects sub-heading, in ER order within each tier.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 620, 625, 628, and 634.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare headings only; the ER’s incidence figures (1 of 6 subjects, 40–42%, grade 3 in 2 of 4 patients) are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any of the four risk tiers.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers carry items, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows trace to the ER Monitoring Protocol & Defining Success biomarker table (lines 389–399).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table rows are carried, in ER order, with the “Optimal Functional Range” and “Why Measure It?” values reproduced verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 784–788 condense the ER’s cadence narrative (line 387): baseline, 4–6 week sodium and thyroid recheck, 3-month metabolite ratio, annual thereafter, with a repeat 4–6 week check after any dose increase.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the qualitative marker list at ER lines 403–407.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers — cycle-related symptoms, skin, energy and exercise capacity, urine color, and vision — are present and verbatim.

Issues 09/09/2026 04:19

Pass rate 100.00%. No issues found.